|
private:pixiumvision
|
5230397
|
May 31st, 2019 12:00AM
|
Pixium Vision S.A.
|
1.6K
|
38.00
|
Open
|
Medical Devices
|
May 30th, 2019 11:43PM
|
May 30th, 2019 11:43PM
|
One must remember the notion that restoring some vision to those who have lost their sight is possible, has long been thought to be fanciful. However, we are in the Age of Neural Prostheses, Bioelectronics, and BMI. At frontier of neuroscience, interfacing the worlds of eye and the brain – “from Photons to Neurons”. Such is the breadth and depth of knowledge needed to build a world of bionic vision for those with vision loss. This is the mission of Pixium Vision.
Two novel life changing Bionic Vision Systems developed, with active implantable prostheses, that are intended to compensate for vision loss and blindness from retinal degeneration, like Dry Age-Related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP), enabling to regain partial central visual perception and lead more independent lives.
Advances in neuro-ophthalmology, innovative state of the art biomedical / bioelectronic technologies, smart bio-inspired bio-mimetic algorithms and AI, and miniaturization of micro/nano-electronics, enable minimal invasive retinal surgery, and develop systems that could provide blind people with a form of prosthetic bionic vision.
• PRIMA (Subretinal) a miniaturized wireless photovoltaic implant platform initially for Dry-AMD. The company is conducting first-in-human feasibility trials in Europe and the US.
• IRIS®II (Epiretinal) its first System for RP, equipped with a bio-inspired camera, an implant with 150 electrodes, designed to be explantable.
Formed in Dec 2011, a bioelectronics technology company specialized in neuromodulation to restore a form of prosthetic vision to compensate for blindness. Listed on Euronext Paris stock exchange in June 2014. Collaborates with a global ecosystem of scientific and clinical partners spanning the prestigious Vision research institutions including: Institut de la Vision Paris, Stanford University California, Moorfields Eye Hospital London, and Institute of Ocular Microsurgery (IMO) Barcelona.
twitter: @PixiumVision
|
Open
|
Ophthalmology, Retina, Bionic Vision, Neuromodulation, Neuroscience, Neurobiology, Artificial Vision, Neuro Opthalmology, Bio hacking, Neuro Ophthalmodulation, Artificial Vision, retinitis pigmentosa, blindness, ophtalmologie, vision restoration, bio electric, Age related Macular Degeneration AMD, bio electronic medicine, Digital Medicine, Sensory Neuromodulation, Bbioelectronics, Dry AMD
|
Open
|
74 Rue du Faubourg Saint-Antoine
|
Paris
|
|
FR
|
75012
|
|
Pixium Vision
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
private:pixiumvision
|
5230397
|
Feb 17th, 2018 12:00AM
|
Pixium Vision S.A.
|
923
|
43.00
|
Open
|
Medical Devices
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
One must remember the notion that restoring some vision to those who have lost their sight is possible, has long been thought to be fanciful. However, we are in the New Age of Neural Prostheses. At frontier of neuroscience, interfacing the worlds of eye and the brain – “from Photons to Neurons”. Such is the breadth and depth of understanding required to build a world of bionic vision for those who have lost their sight. That is the mission of Pixium Vision.
2 innovative Bionic Vision Systems being developed, include active implantable prostheses, intended to treat and compensate for blindness from degenerative retinal diseases like Retinitis Pigmentosa (RP) and Age-Related Macular Degeneration (AMD). The devices are intended for blind people with a functional optic nerve to enable them to regain greater autonomy and improved quality of daily living
The Company harnesses rapid advances in neuroscience, neuromorphic visual processing, micro/nano-electronics, optoelectronics, neurobiology and intelligent software algorithms, to develop systems that could provide blind people with a form of bionic vision
• IRIS®II (Epi-retinal) its first Bionic Vision System equipped with a bio-inspired camera, and an implant with 150 electrodes, designed to be explantable and upgradeable
• PRIMA (sub-retinal) a miniaturized wireless photovoltaic implant platform for Age-related Macular Degeneration (AMD) indication. The company recently completed pre-clinical study phases and plans to initiate first-in-human trials by end 2016.
The proprietary innovative bio-inspired, neuromorphic event-based camera sensor mimics the functioning of the human retina enabling intelligent retinal stimulation.
Created in 2011 incorporating global expertise, knowhow and technologies via global ecosystem of renowned scientists from prestigious academic and technology institutions worldwide, including Institut de la Vision (France) and Stanford University (USA).
twitter: @PixiumVision
|
|
|
|
|
|
|
|
|
|
Pixium Vision
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
private:pixiumvision
|
5230397
|
Feb 16th, 2018 12:00AM
|
Pixium Vision S.A.
|
923
|
43.00
|
Open
|
Medical Devices
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
One must remember the notion that restoring some vision to those who have lost their sight is possible, has long been thought to be fanciful. However, we are in the New Age of Neural Prostheses. At frontier of neuroscience, interfacing the worlds of eye and the brain – “from Photons to Neurons”. Such is the breadth and depth of understanding required to build a world of bionic vision for those who have lost their sight. That is the mission of Pixium Vision.
2 innovative Bionic Vision Systems being developed, include active implantable prostheses, intended to treat and compensate for blindness from degenerative retinal diseases like Retinitis Pigmentosa (RP) and Age-Related Macular Degeneration (AMD). The devices are intended for blind people with a functional optic nerve to enable them to regain greater autonomy and improved quality of daily living
The Company harnesses rapid advances in neuroscience, neuromorphic visual processing, micro/nano-electronics, optoelectronics, neurobiology and intelligent software algorithms, to develop systems that could provide blind people with a form of bionic vision
• IRIS®II (Epi-retinal) its first Bionic Vision System equipped with a bio-inspired camera, and an implant with 150 electrodes, designed to be explantable and upgradeable
• PRIMA (sub-retinal) a miniaturized wireless photovoltaic implant platform for Age-related Macular Degeneration (AMD) indication. The company recently completed pre-clinical study phases and plans to initiate first-in-human trials by end 2016.
The proprietary innovative bio-inspired, neuromorphic event-based camera sensor mimics the functioning of the human retina enabling intelligent retinal stimulation.
Created in 2011 incorporating global expertise, knowhow and technologies via global ecosystem of renowned scientists from prestigious academic and technology institutions worldwide, including Institut de la Vision (France) and Stanford University (USA).
twitter: @PixiumVision
|
|
|
|
|
|
|
|
|
|
Pixium Vision
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
private:pixiumvision
|
5230397
|
Feb 15th, 2018 12:00AM
|
Pixium Vision S.A.
|
923
|
43.00
|
Open
|
Medical Devices
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
One must remember the notion that restoring some vision to those who have lost their sight is possible, has long been thought to be fanciful. However, we are in the New Age of Neural Prostheses. At frontier of neuroscience, interfacing the worlds of eye and the brain – “from Photons to Neurons”. Such is the breadth and depth of understanding required to build a world of bionic vision for those who have lost their sight. That is the mission of Pixium Vision.
2 innovative Bionic Vision Systems being developed, include active implantable prostheses, intended to treat and compensate for blindness from degenerative retinal diseases like Retinitis Pigmentosa (RP) and Age-Related Macular Degeneration (AMD). The devices are intended for blind people with a functional optic nerve to enable them to regain greater autonomy and improved quality of daily living
The Company harnesses rapid advances in neuroscience, neuromorphic visual processing, micro/nano-electronics, optoelectronics, neurobiology and intelligent software algorithms, to develop systems that could provide blind people with a form of bionic vision
• IRIS®II (Epi-retinal) its first Bionic Vision System equipped with a bio-inspired camera, and an implant with 150 electrodes, designed to be explantable and upgradeable
• PRIMA (sub-retinal) a miniaturized wireless photovoltaic implant platform for Age-related Macular Degeneration (AMD) indication. The company recently completed pre-clinical study phases and plans to initiate first-in-human trials by end 2016.
The proprietary innovative bio-inspired, neuromorphic event-based camera sensor mimics the functioning of the human retina enabling intelligent retinal stimulation.
Created in 2011 incorporating global expertise, knowhow and technologies via global ecosystem of renowned scientists from prestigious academic and technology institutions worldwide, including Institut de la Vision (France) and Stanford University (USA).
twitter: @PixiumVision
|
|
|
|
|
|
|
|
|
|
Pixium Vision
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
private:pixiumvision
|
5230397
|
Feb 14th, 2018 12:00AM
|
Pixium Vision S.A.
|
923
|
43.00
|
Open
|
Medical Devices
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
One must remember the notion that restoring some vision to those who have lost their sight is possible, has long been thought to be fanciful. However, we are in the New Age of Neural Prostheses. At frontier of neuroscience, interfacing the worlds of eye and the brain – “from Photons to Neurons”. Such is the breadth and depth of understanding required to build a world of bionic vision for those who have lost their sight. That is the mission of Pixium Vision.
2 innovative Bionic Vision Systems being developed, include active implantable prostheses, intended to treat and compensate for blindness from degenerative retinal diseases like Retinitis Pigmentosa (RP) and Age-Related Macular Degeneration (AMD). The devices are intended for blind people with a functional optic nerve to enable them to regain greater autonomy and improved quality of daily living
The Company harnesses rapid advances in neuroscience, neuromorphic visual processing, micro/nano-electronics, optoelectronics, neurobiology and intelligent software algorithms, to develop systems that could provide blind people with a form of bionic vision
• IRIS®II (Epi-retinal) its first Bionic Vision System equipped with a bio-inspired camera, and an implant with 150 electrodes, designed to be explantable and upgradeable
• PRIMA (sub-retinal) a miniaturized wireless photovoltaic implant platform for Age-related Macular Degeneration (AMD) indication. The company recently completed pre-clinical study phases and plans to initiate first-in-human trials by end 2016.
The proprietary innovative bio-inspired, neuromorphic event-based camera sensor mimics the functioning of the human retina enabling intelligent retinal stimulation.
Created in 2011 incorporating global expertise, knowhow and technologies via global ecosystem of renowned scientists from prestigious academic and technology institutions worldwide, including Institut de la Vision (France) and Stanford University (USA).
twitter: @PixiumVision
|
|
|
|
|
|
|
|
|
|
Pixium Vision
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
private:pixiumvision
|
5230397
|
Feb 13th, 2018 12:00AM
|
Pixium Vision S.A.
|
923
|
43.00
|
Open
|
Medical Devices
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
One must remember the notion that restoring some vision to those who have lost their sight is possible, has long been thought to be fanciful. However, we are in the New Age of Neural Prostheses. At frontier of neuroscience, interfacing the worlds of eye and the brain – “from Photons to Neurons”. Such is the breadth and depth of understanding required to build a world of bionic vision for those who have lost their sight. That is the mission of Pixium Vision.
2 innovative Bionic Vision Systems being developed, include active implantable prostheses, intended to treat and compensate for blindness from degenerative retinal diseases like Retinitis Pigmentosa (RP) and Age-Related Macular Degeneration (AMD). The devices are intended for blind people with a functional optic nerve to enable them to regain greater autonomy and improved quality of daily living
The Company harnesses rapid advances in neuroscience, neuromorphic visual processing, micro/nano-electronics, optoelectronics, neurobiology and intelligent software algorithms, to develop systems that could provide blind people with a form of bionic vision
• IRIS®II (Epi-retinal) its first Bionic Vision System equipped with a bio-inspired camera, and an implant with 150 electrodes, designed to be explantable and upgradeable
• PRIMA (sub-retinal) a miniaturized wireless photovoltaic implant platform for Age-related Macular Degeneration (AMD) indication. The company recently completed pre-clinical study phases and plans to initiate first-in-human trials by end 2016.
The proprietary innovative bio-inspired, neuromorphic event-based camera sensor mimics the functioning of the human retina enabling intelligent retinal stimulation.
Created in 2011 incorporating global expertise, knowhow and technologies via global ecosystem of renowned scientists from prestigious academic and technology institutions worldwide, including Institut de la Vision (France) and Stanford University (USA).
twitter: @PixiumVision
|
|
|
|
|
|
|
|
|
|
Pixium Vision
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
private:pixiumvision
|
5230397
|
Feb 12th, 2018 12:00AM
|
Pixium Vision S.A.
|
923
|
43.00
|
Open
|
Medical Devices
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
One must remember the notion that restoring some vision to those who have lost their sight is possible, has long been thought to be fanciful. However, we are in the New Age of Neural Prostheses. At frontier of neuroscience, interfacing the worlds of eye and the brain – “from Photons to Neurons”. Such is the breadth and depth of understanding required to build a world of bionic vision for those who have lost their sight. That is the mission of Pixium Vision.
2 innovative Bionic Vision Systems being developed, include active implantable prostheses, intended to treat and compensate for blindness from degenerative retinal diseases like Retinitis Pigmentosa (RP) and Age-Related Macular Degeneration (AMD). The devices are intended for blind people with a functional optic nerve to enable them to regain greater autonomy and improved quality of daily living
The Company harnesses rapid advances in neuroscience, neuromorphic visual processing, micro/nano-electronics, optoelectronics, neurobiology and intelligent software algorithms, to develop systems that could provide blind people with a form of bionic vision
• IRIS®II (Epi-retinal) its first Bionic Vision System equipped with a bio-inspired camera, and an implant with 150 electrodes, designed to be explantable and upgradeable
• PRIMA (sub-retinal) a miniaturized wireless photovoltaic implant platform for Age-related Macular Degeneration (AMD) indication. The company recently completed pre-clinical study phases and plans to initiate first-in-human trials by end 2016.
The proprietary innovative bio-inspired, neuromorphic event-based camera sensor mimics the functioning of the human retina enabling intelligent retinal stimulation.
Created in 2011 incorporating global expertise, knowhow and technologies via global ecosystem of renowned scientists from prestigious academic and technology institutions worldwide, including Institut de la Vision (France) and Stanford University (USA).
twitter: @PixiumVision
|
|
|
|
|
|
|
|
|
|
Pixium Vision
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
private:pixiumvision
|
5230397
|
Feb 11th, 2018 12:00AM
|
Pixium Vision S.A.
|
923
|
43.00
|
Open
|
Medical Devices
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
One must remember the notion that restoring some vision to those who have lost their sight is possible, has long been thought to be fanciful. However, we are in the New Age of Neural Prostheses. At frontier of neuroscience, interfacing the worlds of eye and the brain – “from Photons to Neurons”. Such is the breadth and depth of understanding required to build a world of bionic vision for those who have lost their sight. That is the mission of Pixium Vision.
2 innovative Bionic Vision Systems being developed, include active implantable prostheses, intended to treat and compensate for blindness from degenerative retinal diseases like Retinitis Pigmentosa (RP) and Age-Related Macular Degeneration (AMD). The devices are intended for blind people with a functional optic nerve to enable them to regain greater autonomy and improved quality of daily living
The Company harnesses rapid advances in neuroscience, neuromorphic visual processing, micro/nano-electronics, optoelectronics, neurobiology and intelligent software algorithms, to develop systems that could provide blind people with a form of bionic vision
• IRIS®II (Epi-retinal) its first Bionic Vision System equipped with a bio-inspired camera, and an implant with 150 electrodes, designed to be explantable and upgradeable
• PRIMA (sub-retinal) a miniaturized wireless photovoltaic implant platform for Age-related Macular Degeneration (AMD) indication. The company recently completed pre-clinical study phases and plans to initiate first-in-human trials by end 2016.
The proprietary innovative bio-inspired, neuromorphic event-based camera sensor mimics the functioning of the human retina enabling intelligent retinal stimulation.
Created in 2011 incorporating global expertise, knowhow and technologies via global ecosystem of renowned scientists from prestigious academic and technology institutions worldwide, including Institut de la Vision (France) and Stanford University (USA).
twitter: @PixiumVision
|
|
|
|
|
|
|
|
|
|
Pixium Vision
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
private:pixiumvision
|
5230397
|
Feb 10th, 2018 12:00AM
|
Pixium Vision S.A.
|
923
|
43.00
|
Open
|
Medical Devices
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
One must remember the notion that restoring some vision to those who have lost their sight is possible, has long been thought to be fanciful. However, we are in the New Age of Neural Prostheses. At frontier of neuroscience, interfacing the worlds of eye and the brain – “from Photons to Neurons”. Such is the breadth and depth of understanding required to build a world of bionic vision for those who have lost their sight. That is the mission of Pixium Vision.
2 innovative Bionic Vision Systems being developed, include active implantable prostheses, intended to treat and compensate for blindness from degenerative retinal diseases like Retinitis Pigmentosa (RP) and Age-Related Macular Degeneration (AMD). The devices are intended for blind people with a functional optic nerve to enable them to regain greater autonomy and improved quality of daily living
The Company harnesses rapid advances in neuroscience, neuromorphic visual processing, micro/nano-electronics, optoelectronics, neurobiology and intelligent software algorithms, to develop systems that could provide blind people with a form of bionic vision
• IRIS®II (Epi-retinal) its first Bionic Vision System equipped with a bio-inspired camera, and an implant with 150 electrodes, designed to be explantable and upgradeable
• PRIMA (sub-retinal) a miniaturized wireless photovoltaic implant platform for Age-related Macular Degeneration (AMD) indication. The company recently completed pre-clinical study phases and plans to initiate first-in-human trials by end 2016.
The proprietary innovative bio-inspired, neuromorphic event-based camera sensor mimics the functioning of the human retina enabling intelligent retinal stimulation.
Created in 2011 incorporating global expertise, knowhow and technologies via global ecosystem of renowned scientists from prestigious academic and technology institutions worldwide, including Institut de la Vision (France) and Stanford University (USA).
twitter: @PixiumVision
|
|
|
|
|
|
|
|
|
|
Pixium Vision
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
private:pixiumvision
|
5230397
|
Feb 9th, 2018 12:00AM
|
Pixium Vision S.A.
|
923
|
43.00
|
Open
|
Medical Devices
|
Feb 9th, 2017 08:57AM
|
Feb 9th, 2017 08:57AM
|
One must remember the notion that restoring some vision to those who have lost their sight is possible, has long been thought to be fanciful. However, we are in the New Age of Neural Prostheses. At frontier of neuroscience, interfacing the worlds of eye and the brain – “from Photons to Neurons”. Such is the breadth and depth of understanding required to build a world of bionic vision for those who have lost their sight. That is the mission of Pixium Vision.
2 innovative Bionic Vision Systems being developed, include active implantable prostheses, intended to treat and compensate for blindness from degenerative retinal diseases like Retinitis Pigmentosa (RP) and Age-Related Macular Degeneration (AMD). The devices are intended for blind people with a functional optic nerve to enable them to regain greater autonomy and improved quality of daily living
The Company harnesses rapid advances in neuroscience, neuromorphic visual processing, micro/nano-electronics, optoelectronics, neurobiology and intelligent software algorithms, to develop systems that could provide blind people with a form of bionic vision
• IRIS®II (Epi-retinal) its first Bionic Vision System equipped with a bio-inspired camera, and an implant with 150 electrodes, designed to be explantable and upgradeable
• PRIMA (sub-retinal) a miniaturized wireless photovoltaic implant platform for Age-related Macular Degeneration (AMD) indication. The company recently completed pre-clinical study phases and plans to initiate first-in-human trials by end 2016.
The proprietary innovative bio-inspired, neuromorphic event-based camera sensor mimics the functioning of the human retina enabling intelligent retinal stimulation.
Created in 2011 incorporating global expertise, knowhow and technologies via global ecosystem of renowned scientists from prestigious academic and technology institutions worldwide, including Institut de la Vision (France) and Stanford University (USA).
twitter: @PixiumVision
|
|
|
|
|
|
|
|
|
|
Pixium Vision
|
Health Care
|
Pharmaceuticals & Biotechnology
|